Jazzpharma stock.

Based on 8 Wall Street analysts offering 12 month price targets for Jazz Pharmaceuticals in the last 3 months. The average price target is $210.29 with a high forecast of $225.00 and a low forecast of $191.00. The average price target represents a 73.29% change from the last price of $121.35. Highest Price Target $225.00.

Jazzpharma stock. Things To Know About Jazzpharma stock.

Real-Time News, Market Data, and Stock Quotes for Life Science Stocks @ healthstockshub.com Jazz Pharmaceuticals to Present Long-Term and Real-World Data Emphasizing Commitment to Treatment-Resistant Epilepsy at the 2023 American Epilepsy Society Annual Meeting - Health Stocks HubJazz Pharma agreed in 2021 to acquire GW Pharmaceuticals Plc, the maker of the first drug derived from the cannabis plant to win approval in the US, for $7.2 billion in cash and stock. Jazz Pharma ...See Jazz Pharmaceuticals plc (JAZZ) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.118.66 PREV. CLOSE 118.27 VOLUME 592,901.00 MARKET CAP 7.663B DAY RANGE 118.33 – 122.34 52 WEEK RANGE 115.97 – 160.96 Key Statistics P/E Ratio 15.30 Shares Outstanding 62.957M Price to Book Ratio...

If you want to keep up to date on the stock market you have a device in your pocket that makes that possible. Your phone can track everything finance-related and help keep you up to date on the world markets.Investor Contacts. Andrea N. Flynn, Ph.D. Vice President, Head, Investor Relations. [email protected] Ireland: +353 1 634 3211 U.S.: +1 650 496 2717Jazz’s narcolepsy drug, which is used by thousands of patients, is enormously lucrative, generating more than $13 billion in revenue since Jazz acquired it in 2005. Medicare now spends hundreds ...

Jazz Pharmaceuticals will host an investor conference call and live audio webcast today at 4:30 p.m. ET ( 9:30 p.m. GMT) to provide a business and financial update and discuss its 2023 third ...

Earnings Gainers. Earnings Stalwarts. Safe (er) Stocks. Top Dividend Stocks. Stocks Under $10. Defensive Picks. Compare stocks to their industry peers at U.S. News Best Stocks.Corporate Headquarters Jazz Pharmaceuticals plc is registered in Ireland, No. 399192. V.A.T. Registration number: 6419192A Registered office: Waterloo Exchange, Waterloo Road, Dublin 4 Tel: +35 31 634 7800 Email: [email protected] Europe & International Headquarters Wing B, Building 5700 Spires House John Smith …Jazz Pharmaceuticals plc (JAZZ) NasdaqGS - NasdaqGS Real Time Price. Currency in USD Follow 2W 10W 9M 121.35 -0.37 (-0.30%) At close: 01:00PM EST 123.45 +2.10 (+1.73%) After hours: 01:20PM EST 1d...0. These 4 analysts have an average price target of $194.0 versus the current price of Jazz Pharmaceuticals at $114.38, implying upside. Below is a summary of how these 4 analysts rated Jazz ...

73.07. -2.42%. 8.08M. View today's Jazz Pharmaceuticals PLC stock price and latest JAZZ news and analysis. Create real-time notifications to follow any changes in the live stock price.

The Jazz Pharmaceuticals 52-week high stock price is 160.96, which is 36.1% above the current share price. The Jazz Pharmaceuticals 52-week low stock price is 111.25, which is 5.9% below the current share price. The average Jazz Pharmaceuticals stock price for the last 52 weeks is 137.69. For more information on how our historical price data is ...

Based on 8 Wall Street analysts offering 12 month price targets for Jazz Pharmaceuticals in the last 3 months. The average price target is $210.29 with a high forecast of $225.00 and a low forecast of $191.00. The average price target represents a 73.29% change from the last price of $121.35. Highest Price Target $225.00.Jazz Pharmaceuticals Stock (NASDAQ: JAZZ) stock price, news, charts, stock research, profile. ... Jazz Pharma enters collaboration to develop neurological drugs. Seeking Alpha - Nov 14, ...Nov 30, 2023 · Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Company’s lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn ... NVDA. NVIDIA Corporation Common Stock. $443.09 -12.11 -2.66%. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market ... Stock Information; Corporate Sustainability and Social Impact; Resources; FAQs; Email Alerts; Information Request; Analyst Coverage; ... [email protected] Ireland: +353 1 634 3211 U.S.: +1 650 496 2717 . Annual Reports 2022 Annual Report 3.3 MB. 2021 Annual Report 5 MB.Real time Jazz Pharmaceuticals Plc (JAZZ) stock price quote, stock graph, news & analysis.

Feb 3, 2021 · Jazz Pharmaceuticals PLC has agreed to acquire GW Pharmaceuticals PLC, maker of the first epilepsy drug derived from the marijuana plant, for $6.7 billion in cash and stock. The deal, combining ... 119.00 PREV. CLOSE 121.35 VOLUME 610,337.00 MARKET CAP 7.4B DAY RANGE 117.02 – 120.14 52 WEEK RANGE 115.97 – 160.96 Key Statistics P/E …WebAccording to 8 analysts, the average rating for JAZZ stock is "Strong Buy." The 12-month stock price forecast is $202.29, which is an increase of 66.70% from the …WebJazz Pharmaceuticals, Inc is committed to providing our employees with a benefits program that is comprehensive, competitive and demonstrates care for the health of our employees and their families. 401K Savings Plan. Equity Grants: RSU. ESSP.View Jazz Pharmaceuticals PLC JAZZ investment & stock information. Get the latest Jazz Pharmaceuticals PLC JAZZ detailed stock quotes, stock data, Real-Time ECN, charts, stats and [email protected] Ireland: +353 1 634 3211 ... NOTE: The Closing Price, Day's High, Day's Low, and Day's Volume have been adjusted to account for any stock splits and/or dividends which may have occurred for this security since the date shown. The Split Adjustment Factor is a cumulative factor which encapsulates all splits since the ...

August 12, 2019. DUBLIN, Aug. 12, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the acquisition of Cavion, Inc. through a merger with a Jazz subsidiary. Under the terms of the agreement, the former Cavion shareholders receive an upfront payment of $52.5 million and have the potential to receive additional payments ...

Top Pharmaceuticals & Drugs Stocks in India by Market Capitalisation: Get the List of Top Pharmaceuticals & Drugs Companies in India (BSE) based on Market CapitalisationWe are advancing a novel class of cancer biotherapeutics designed to enhance the body’s immune response to cancer. These conditionally activated proinflammatory immune modulators, called INDUKINE™ molecules, are systemically administered in an inactive form and are selectively activated to deliver full biological …Nov 8, 2023 · Jazz Pharmaceuticals will host an investor conference call and live audio webcast today at 4:30 p.m. ET ( 9:30 p.m. GMT) to provide a business and financial update and discuss its 2023 third ... 28 Mei 2015 ... Six years later, with a market cap over $11.3 billion, the stock trading over $180 a share, and Jazz being viewed as one of the hottest Big ...12517 Total Market Cap: $85.7T. Login. Rank by CountryIn 2022, the biotech reported total revenue of $3.7 billion, an 18% year-over-year increase. The company did report a net loss for the year, which came in at $3.58 per share, slightly better than ...

This represents a premium of approximately 50 percent over GW's closing stock price on February 2, 2021, ... For more information, please visit www.jazzpharmaceuticals.com and follow @JazzPharma on Twitter. About GW Pharmaceuticals plc Founded in 1998, GW is a biopharmaceutical company focused on …

When it comes to purchasing a new vehicle, finding the perfect car that meets all your requirements can be a daunting task. If you have your heart set on a Genesis GV70, you’ll want to ensure that you find the best one available in stock.

intraday 1w 1m 6m ytd 1y 3y 5y max Mountain-Chart Compare with Compare with up to 5 Stocks On Friday 11/17/2023 the closing price of the Jazz Pharmaceuticals PLC share was $120.56 on NAS....According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $194.86. View Our Latest Report on Jazz Pharmaceuticals. Jazz Pharmaceuticals Trading Up 0.7 %. NASDAQ:JAZZ opened at $119.11 on Monday. The company has a debt-to-equity ratio of 1.46, a quick ratio of 1.67 and a current ratio of …Morningstar has a "buy" rating and $54 fair value estimate for GSK stock, which closed at $37.10 on Oct. 9. Dividend yield: 3.8% 10 Best Health Care Stocks to BuyDiscover historical prices for JAZZ stock on Yahoo Finance. View daily, weekly or monthly format back to when Jazz Pharmaceuticals plc stock was issued.3 Feb 2021 ... ... stock. That works out to a roughly 50% premium over GW's Tuesday closing price. RELATED: GW's Epidiolex topped sales predictions, but ...2003. 2,800. Bruce Cozadd. https://www.jazzpharma.com. Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product …Jazz Pharmaceuticals (NASDAQ:JAZZ) has observed the following analyst ratings within the last quarter: These 6 analysts have an average price target of $207.83 versus the current price of Jazz ...Investing in the stock market takes a lot of courage, a lot of research, and a lot of wisdom. One of the most important steps is understanding how a stock has performed in the past. Of course, the past is not a guarantee of future performan...

Real time Jazz Pharmaceuticals Plc (JAZZ) stock price quote, stock graph, news & analysis.Altimmune Joins Weight-Loss Race with Phase II Win, Stock Jumps on News 12/1/2023 Patients treated with Altimmune’s investigational GLP-1/glucagon dual receptor agonist saw up to 15.6% weight loss, and nearly a third of those taking the highest dose lost at least 20% of their body [email protected] Ireland, +353 1 697 2141 U.S. +1 215 867 4910. Investors: Andrea N. Flynn, Ph.D. Vice President, Head, Investor Relations Jazz Pharmaceuticals plc [email protected] Ireland +353 1 634 3211. References: Xywav (calcium, magnesium, potassium and sodium oxybates) oral …Jazz Pharmaceuticals Germany GmbH c/o Design Offices Einsteinstrasse 174 81677 München Tel: +49 89 41109660 Customer Services Tel: +49 89 41109674 Fax: + 49 89 41109661 Email: [email protected] For Medical Information Requests in Germany or Austria please click here. To Report an Adverse Event or Product …Instagram:https://instagram. pure storage earningspfe ex dividend datemodel y inventorynewest etfs Jazz Pharmaceuticals plc (JAZZ) NasdaqGS - NasdaqGS Real Time Price. Currency in USD Follow 2W 10W 9M 118.23 +3.97 (+3.47%) At close: 04:00PM EST 117.70 -0.53 ( …WebIn a report released yesterday, Needham also maintained a Buy rating on the stock with a $225.00 price target. ... Autifony Signs Up To $770 Mln Worth Global Licencing Deal With Jazz Pharma . betterment vs schwabsmart shop self storage Feb 5, 2021 · Jazz Pharmaceuticals brought in approximately $1.8 billion and $565 million, respectively, from its neuroscience and oncology segments in 2020. Those are sizable increases from the $1.65 billion ... Investor Contacts. Andrea N. Flynn, Ph.D. Vice President, Head, Investor Relations. [email protected] Ireland: +353 1 634 3211 U.S.: +1 650 496 2717 option call calculator The formula for return on equity is: Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity. So, based on the above formula, the ROE for Jazz Pharmaceuticals is: 2.3% = US$80m ÷ US$3.5b (Based on the trailing twelve months to September 2023). The 'return' is the amount earned after tax over the last twelve months.Morningstar has a "buy" rating and $54 fair value estimate for GSK stock, which closed at $37.10 on Oct. 9. Dividend yield: 3.8% 10 Best Health Care Stocks to BuyCurrently, Jazz Pharmaceuticals PLC’s price-earnings ratio is 202.2. Jazz Pharmaceuticals PLC’s trailing 12-month revenue is $3.8 billion with a 2.1% profit margin. Year-over-year quarterly sales growth most recently was 3.3%. Analysts expect adjusted earnings to reach $18.444 per share for the current fiscal year.